超声微创介入治疗复发性肝癌的近远期疗效分析  

Immediate and long-term outcomes of Ultrasound-assisted selective artery embolization chemotherapy combined with radiofrequency ablation for recurrent liver cancer

作　　者：严稳开 周静[1] 

机构地区：[1]湖北省鄂州市中心医院超声科,鄂州市436000

出　　处：《微创医学》2014年第6期717-719,共3页Journal of Minimally Invasive Medicine

摘　　要：目的探讨复发性肝癌患者进行超声微创介入疗法的近远期临床效果。方法选择复发性肝癌患者102例,按随机数字表法分为观察组和对照组各61例。观察组应用超声微创介入联合动脉栓塞化疗法,对照组实施单纯动脉栓塞化疗法,比较两组患者疗效和治疗后生存率情况。结果观察组和对照组的临床有效率分别为76.5%、52.9%,差异有统计学意义(P<0.05);治疗后观察组的1年、3年、5年生存率显著高于对照组,差异有统计学意义(P<0.05);观察组、对照组的术后并发症发生率分别为11.8%、9.8%,差异无统计学意义(P>0.05),术后出现并发症患者经积极抗炎、保肝、补液治疗后好转。结论超声微创介入疗法治疗复发性肝癌晚期患者临床效果确切,治疗后生存率高,可延缓病情进展,值得临床推广应用。Objective To study the immediate and long-term outcomes of Ultrasound-assisted selective artery embolization chemotherapy combined with radiofrequency ablation for recurrent liver cancer.Methods Between January 2011 and January 2014,102 patients with recurrent liver cancer were randomly divided into observation group and control group,61 cases in each group. Ultrasound-assisted selective artery embolization chemotherapy combined with radiofrequency ablation was used in observation group,arterial embolism chemotherapy soley was used in control group. Results The clinical effectiveness of observation group and control group were 76. 5%,52. 9% respectively,showing significant difference（ P 〈 0. 05）. The survival rates of 1 year,3 years and 5 years of survival rate in treatment group were significantly higher than the control group（ P 〈 0. 05）. Conclusion Ultrasound-assisted selective artery embolization chemotherapy combined with radiofrequency ablation for recurrent liver cancer ter treatment can delay progression,prolong survival,worthy of clinical promotion.

关 键 词：临床效果 复发性肝癌 超声微创介入疗法 

分 类 号：R735.7[医药卫生—肿瘤]